NCCN Guidelines® Updates: Management of Metastatic Colorectal Cancer
The approval of new therapies has substantially expanded the treatment options for metastatic colorectal cancer (mCRC) in recent years, raising new questions about how to select the most appropriate therapy for a specific patient and how to optimally sequence these therapies.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Biomarker Testing for Immunotherapy
Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.
Category
  • Bladder Cancer
  • Colorectal Cancer
  • Gynecologic Cancers
  • Kidney Cancer
  • Lung Cancers
  • Melanoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Clinical Updates: Metastatic Colorectal Cancer
Each of the therapies for mCRC are associated with certain toxicities, many of which differ depending on the mechanism of action; therefore, the supportive care needs of patients receiving systemic therapy for mCRC vary.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019
Identifying individuals with hereditary syndromes allows for improved cancer surveillance, risk reduction, and optimized management. Establishing criteria for assessment allows for the identification of individuals who are carriers of pathogenic genetic variants.
Category
  • Colorectal Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Colorectal Cancer
Personalizing treatment selection for each patient with localized colon cancer or metastatic colorectal cancer (mCRC) can maximize the benefits while minimizing the harms to give each patient the best survival and quality of life possible. Clinicians must be knowledgeable about new trial results, new systemic therapy options, new biomarkers, and other treatment-selection criteria in order to help patients make the best informed decisions possible.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation